Sandoz releases bimatoprost solution in U.S.
"The launch of bimatoprost is an important addition to our industry-leading portfolio of ophthalmic products,” Sandoz President Peter Goldschmidt said. “By expanding our ophthalmic offerings, Sandoz will increase patients’ access to a comprehensive range of quality medicines at affordable prices.”
Bimatoprost ophthalmic solution, 0.03 percent, was designed to help the growth, length, thickness and darkness of eyelashes for the treatment of hypotrichosis of the eyelashes.
Latisse had approximately $75 million in sales in the United States for a 12-month period that ended in October according to IMS Health. Bimatoprost will be marketed with 0.03 percent strength, the same as Latisse.